These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36529704)

  • 61. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
    Quezada G; Kopp L; Estey E; Wells RJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Walking a Tightrope: Dosage Modifications and Treatment Outcomes of All-
    Danthala M; Golamari KR; Seshachalam A; Mikkilineni A; Chappidi S; Mekala MB; Elangovan V; Chinnakali P
    JCO Glob Oncol; 2020 Nov; 6():1749-1756. PubMed ID: 33201743
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.
    Coutre SE; Othus M; Powell B; Willman CL; Stock W; Paietta E; Levitan D; Wetzler M; Attar EC; Altman JK; Gore SD; Maher T; Kopecky KJ; Tallman MS; Larson RA; Appelbaum FR
    Br J Haematol; 2014 May; 165(4):497-503. PubMed ID: 24528179
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
    Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An efficient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid.
    Wang G; Li W; Cui J; Gao S; Yao C; Jiang Z; Song Y; Yuan CJ; Yang Y; Liu Z; Cai L
    Hematol Oncol; 2004 Jun; 22(2):63-71. PubMed ID: 15468344
    [TBL] [Abstract][Full Text] [Related]  

  • 66. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
    Xu LW; Su YZ; Tao HF
    Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Clinical Analysis of Children with High-Risk Acute Promyelocytic Leukemia].
    Gao QL; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):33-37. PubMed ID: 36765473
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy.
    Cicconi L; Divona M; Ciardi C; Ottone T; Ferrantini A; Lavorgna S; Alfonso V; Paoloni F; Piciocchi A; Avvisati G; Ferrara F; Di Bona E; Albano F; Breccia M; Cerqui E; Sborgia M; Kropp MG; Santoro A; Levis A; Sica S; Amadori S; Voso MT; Mandelli F; Lo-Coco F
    Leukemia; 2016 Oct; 30(10):1987-1992. PubMed ID: 27133819
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
    Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.
    Breccia M; Foà R
    Expert Rev Hematol; 2019 Feb; 12(2):81-87. PubMed ID: 30572725
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen.
    Dunn-Valadez S; Bathini S; Purdy KE; Bachiashvili K; Bhatia R; Jamy O; Rangaraju S; Mehta A; Godby K; Goyal G; Worth S; Oliver JD; Mikhail FM; Choi JK; Morlote D; Reddy VB; Vachhani P
    Leuk Lymphoma; 2023 Oct; 64(10):1673-1680. PubMed ID: 37493540
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
    Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
    Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
    Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
    Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
    Chen X; Hong Y; Zheng P; You X; Feng J; Huang Z; Wang Y
    Cancer; 2020 Jan; 126(2):311-321. PubMed ID: 31714584
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Insights into the All-trans-Retinoic Acid and Arsenic Trioxide Combination Treatment for Acute Promyelocytic Leukemia: A Meta-Analysis.
    Ma H; Yang J
    Acta Haematol; 2015; 134(2):101-8. PubMed ID: 25925330
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death.
    Min GJ; Cho BS; Park SS; Park S; Jeon YW; Yahng SA; Shin SH; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim HJ
    Ann Hematol; 2020 May; 99(5):973-982. PubMed ID: 32270215
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Tao S; Wang C; Chen Y; Deng Y; Song L; Shi Y; Ling L; Ding B; He Z; Yu L
    Leuk Lymphoma; 2019 Mar; 60(3):711-719. PubMed ID: 30407095
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?
    Breccia M; Cicconi L; Lo-Coco F
    Curr Opin Hematol; 2014 Mar; 21(2):95-101. PubMed ID: 24434605
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
    Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
    Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
    Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
    Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.